Phase 2 Head and Neck Cancer Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People who have been newly diagnosed with squamous cell carcinoma (a specific type of cancer) in areas such as the mouth, throat, voice box, nasal cavities, or a related area where the original source of the cancer is unknown.
• People whose cancer is at stage III or stage IV (but has not spread to distant parts of the body), or — for those whose throat cancer is linked to the HPV virus — stage II or stage III.
• People whose doctor has determined that starting with systemic (whole-body) treatment before the main cancer treatment makes sense, based on factors such as tumour size, how fast the cancer is growing, or symptoms.
• People whose tumour tests show a CPS score of 1% or higher (a measure of certain proteins on cancer cells — the trial site can explain this further).
• People aged 18 or older.
• People who are generally well enough to carry out normal daily activities, with only minor limitations (this is measured on a standard medical scale called ECOG, score of 0 or 1).
• People who are expected to live for more than 12 weeks.
• People whose blood counts and organ function (including liver and kidney) meet the minimum levels required by the trial (the trial site will check these through blood tests).
• People who have had or currently have another type of cancer, as long as that cancer or its treatment is unlikely to affect the safety or results of this trial.
• People who are willing and able to use reliable contraception (such as hormonal methods, barrier methods, or abstinence) during the trial and for a set period afterward, and who agree to inform their treating doctor immediately if pregnancy occurs or is suspected.
• People who are able to understand the trial information and are willing to sign a consent form agreeing to take part.

Who may not be able to join:

• People whose nasopharynx cancer is linked to the Epstein-Barr virus (EBV).
• People whose cancer is strongly suspected or confirmed to have started in the skin (cutaneous squamous cell carcinoma).
• People whose cancer is a type other than squamous cell carcinoma.
• People whose cancer has already spread to distant parts of the body below the collarbone.
• People who have previously had radiation treatment to the head or neck in an area that overlaps with where the current cancer is located (prior radiation to an unrelated skin cancer in a non-overlapping area may be acceptable — confirm with trial site).
• People who already have moderate or severe nerve damage (numbness, tingling, or pain in the hands or feet) before the trial begins.
• People who are already taking part in another clinical trial using a different experimental treatment for this cancer.
• People who have had a significant allergic reaction to medicines that are chemically similar to the trial drugs (toripalimab, cisplatin, or docetaxel).
• People who have an autoimmune condition that required treatment with steroid tablets or injections within the past 30 days (long-term low-dose steroids for adrenal gland conditions may be acceptable — confirm with trial site).
• People who have had another cancer that required active cancer treatment within the past 6 months.
• People who are taking certain medicines that strongly affect how the body processes the trial drug docetaxel (known as CYP3A4 inhibitors or inducers) — the trial site can advise on specific medicines.
• People who are pregnant, as the trial drugs carry risks of serious harm to an unborn baby.
• People who are breastfeeding, as the trial drugs may carry risks for nursing infants.

Important: Always verify eligibility with the trial site directly before applying.